Drug firm Claris Lifesciences today said it underwent an audit by the USFDA for Pharmacovigilance in the last week of May and has not received any observations.
"Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s)," the company said in a BSE filing.
Shares of the company were trading 4.62 per cent higher at Rs 342.15 apiece on BSE today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
